Skip to Main Content
Yale School of Medicine
YSM Home

INFORMATION FOR

Daniel P. Petrylak, MD

Professor of Medicine (Medical Oncology) and of Urology
DownloadHi-Res Photo

Are You a Patient?

View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

View Doctor Profile

Additional Titles

Chief, Genitourinary Oncology

About

Titles

Professor of Medicine (Medical Oncology) and of Urology

Chief, Genitourinary Oncology

Biography

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.”

At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says.

Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also a member of the Cancer Signaling Networks Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs.

One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.”

Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.

Appointments

  • Medical Oncology

    Professor
    Primary

  • Urology

    Professor
    Secondary

Other Departments & Organizations

Education & Training

Fellowship
Memorial Sloan-Kettering Cancer Center (1991)
Residency
Bronx Municipal Hospital (1988)
Internship
Bronx Municipal Hospital (1986)
MD
Case Western Reserve University School of Medicine (1985)

Research

Overview

Medical Research Interests

Clinical Trial; Medical Oncology; Prostatic Neoplasms; Signal Transduction; Urinary Bladder Neoplasms; Urology

Research at a Glance

Yale Co-Authors

Frequent collaborators of Daniel P. Petrylak's published research.

Publications

2024

See All Publications

Clinical Trials

Current Trials

See All Current Clinical Trials

Clinical Care

Overview

As Professor of Medicine and Urology at Yale School of Medicine, Dr. Daniel P. Petrylak is a pioneer in the research and development of new drugs and treatments to fight prostate, bladder, kidney and testicular cancer. For patients fighting these types of cancers, Petrylak finds recent developments in the field of immunotherapy particularly promising. “Up until recently, bladder cancer had not seen any major advancement in more than 30 years,” he says. “Studies are ongoing, but interim results are exciting so far.”

At the Smilow Cancer Hospital, Dr. Petrylak’s position as a national leader on clinical trials for men with prostate and bladder cancer has opened up a world of treatment options for patients in New England. “We offer the latest investigational drugs for these conditions, while providing the highest level of care,” he says.

Dr. Petrylak received his MD from Case Western Reserve University School of Medicine and joined the Yale faculty in 2012. In addition to his role as professor, he is also the co-director of the Signal Transduction Research Program at Yale Cancer Center, which studies how cancer stem cells are regulated in the body and communicate with surrounding tissue. Roughly 40 physicians and scientists in the program work together to develop the best methods for matching patients with the appropriate cancer drugs.

One of Dr. Petrylak’s key goals is to continue to successfully translate basic research into clinical practice. “One of the most significant accomplishments in my career was moving docetaxel (an antineoplastic agent) therapy for the most advanced form of prostate cancer from phase I to III,” he says. “We ran a trial which supported its approval for the most advanced form of prostate cancer.”

Dr. Petrylak currently serves as either the principal investigator or co-principal investigator on seven Southwest Oncology Group (SWOG) clinical trials for genitourinary cancers. To date, he has authored more than 100 peer-reviewed articles on prostate and bladder cancer research.

Clinical Specialties

Medical Oncology; Urology

Fact Sheets

See All Fact Sheets On Yale Medicine

Board Certifications

  • Medical Oncology

    Certification Organization
    AB of Internal Medicine
    Latest Certification Date
    2023
    Original Certification Date
    1993

Yale Medicine News

See All News On Yale Medicine

Are You a Patient?

View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

View Doctor Profile

Get In Touch

Contacts

Email
Appointment Number
Clinic Fax Number

Locations

  • Patient Care Locations

    Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.

    See Patient Care Locations